Evaluation of chemotherapy response in osteosarcoma with FDG-PET
- 1 January 2009
- journal article
- clinical trial
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 23 (1) , 89-95
- https://doi.org/10.1007/s12149-008-0213-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission TomographyJournal of Clinical Oncology, 2006
- Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapyCancer, 2006
- FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphomaAnnals of Oncology, 2005
- Evaluation of chemotherapy response in pediatric bone sarcomas by [F‐18]‐fluorodeoxy‐D‐glucose positron emission tomographyCancer, 2002
- Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomographyHead & Neck, 1997
- Prognostic factors in osteosarcoma: a critical review.Journal of Clinical Oncology, 1994
- Extremity osteosarcoma in childhood: prognostic value of radiologic imaging.Radiology, 1993
- Musculoskeletal neoplasms after intraarterial chemotherapy: correlation of MR images with pathologic specimens.Radiology, 1990
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986
- Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy. Radiological-pathological correlation in 63 patients.Radiology, 1982